National centralized drug procurement involves diversified drug types and wide geographical area, which provides important reference for regional alliances to carry out centralized procurement. This paper takes the expansion of “4+7” centralized procurement, the second to fifth batch of national centralized drug procurements, and the centralized drug procurement of regional alliances with official data published before December 2021 as examples. OLS regression model is used to analyze whether national centralized drug procurements would have a price transmission effect on the centralized drug procurements of regional alliances. The result shows that there is no significant price transmission effect between national centralized drug procurements and the regional ones. However, this result may not completely deny the existence of price transmission effect due to limited available data, along with few overlapping drug types, different purchase amount and selection rules among the studied drug procurements. This paper aims to enrich the understanding of the connotation and implementation of the centralized drug procurement policy. Meanwhile, it provides some reference for the following centralized drug procurements.